Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. (2014)

First Author: Giagounidis A

Attributed to: MRC Centre for Transplantation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00277-013-1863-5

PubMed Identifier: 24018623

Publication URI: http://europepmc.org/abstract/MED/24018623

Type: Journal Article/Review

Volume: 93

Parent Publication: Annals of hematology

Issue: 1

ISSN: 0939-5555